Cinaver

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinaver

What is Cinaver? Identity, Class, and General Purpose

Cinaver is a commercial name for a medicine containing the active substance Cinnarizine, a synthetic agent primarily known for managing symptoms related to balance and motion sensitivity.

Property Description
Active ingredient Cinnarizine
Form Oral Tablet
Pharmacological class H‑ Antagonist and Calcium Channel Blocker (CCB)
Common use Management of balance disturbances and motion sensitivity
Origin Synthetic compound (Piperazine derivative)

Defining Cinaver: Composition and Origin

Cinaver's core is the single active ingredient Cinnarizine (INN), a synthetic small molecule that belongs to the piperazine derivative family. The preparation is administered orally and typically comes in the physical form of a tablet, consisting of the active crystalline powder combined with various inert solid excipients. This single-ingredient formulation ensures a controlled dose of the drug, which was originally synthesized by Janssen Pharmaceutica.


Pharmacological Class and Dual Action Profile

Cinnarizine is distinctly defined by its placement in a dual pharmacological classification: it functions as both a first-generation Histamine H‑ Antagonist (antihistamine) and a Calcium Channel Blocker (CCB). This dual mechanism represents the medicine's primary characteristic, setting it apart from agents that rely on a single mechanism. The drug’s antihistaminic property contributes to its labyrinthine suppressant action, while its CCB activity allows it to influence regional blood flow, especially in the cerebral and inner ear circulation.


General Therapeutic Purpose of Cinnarizine

Its general therapeutic purpose is to help manage symptoms related to balance disturbances and motion sensitivity. It acts by reducing the sensitivity of the sensory organs in the inner ear and supporting necessary blood flow in the balance centers of the brain. The medicine is utilized as a pharmacotherapy for managing inner ear disorders. This indicates the medicine provides foundational support for stabilizing equilibrium and reducing feelings of spinning and dizziness, making it useful for preventing discomfort before activities that trigger motion sensitivity.

What side effects are possible with Cinaver?

Official Adverse Reactions and Safety Classification

The officially documented safety profile of Cinaver (Cinnarizine) organizes possible adverse reactions based on their frequency and the system-organ class involved, as specified in regulatory labeling. The most frequently observed reactions are classified as common (may affect up to 1 in 10 people) and primarily involve the Nervous System and the Gastrointestinal System.

  • Common Reactions: These include sedation, somnolence, and gastrointestinal disturbances such as nausea and stomach discomfort.
  • Uncommon Reactions: Adverse reactions occurring less frequently include headache, weight gain, and hypersensitivity reactions affecting the skin.
  • Rare Reactions: Regulatory documents list reactions such as cholestatic jaundice, affecting the Hepatobiliary System, and drug-induced lupus erythematosus as rare occurrences.

Safety Considerations for Long-Term Use and Specific Populations

Safety labeling notes specific patterns related to the duration of use. Effects like sedation may be more pronounced at the beginning of treatment. Conversely, the labeling explicitly documents that motor disturbances, including extrapyramidal symptoms (such as tremor and rigidity) and tardive dyskinesia, are more frequently associated with long-term therapy, particularly in older adults.

Official safety restrictions note that use may be contraindicated or requires specific caution in individuals with pre-existing Parkinson's disease, as the medication could potentially worsen existing symptoms. Furthermore, the medicine is restricted for use in patients with known hypersensitivity to Cinnarizine.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected overdose of Cinaver (Cinnarizine), official regulatory labeling mandates that immediate medical attention must be sought. The severity of reported cases has varied, with doses ranging from 90 mg up to 2,250 mg. While consequences are noted as not severe in most instances, regulatory documents confirm that deaths have been reported following both single-drug and polydrug overdoses.

Documented Manifestations and Management

An acute overdose primarily affects the Central Nervous System (CNS), which may manifest as alterations in consciousness ranging from somnolence and stupor up to coma. Other signs include vomiting, extrapyramidal symptoms (involuntary movement disorders), and hypotonia (decreased muscle tone).

The official management protocol is limited to symptomatic and supportive care, as no specific antidote is known for Cinnarizine. In certain contexts, the administration of activated charcoal may be considered. A distinct, population-specific risk exists for young children, in whom seizures (convulsions) have developed following overdose, necessitating that these patients receive observation in a health care facility for potential neurological complications.

Therapeutic Uses of Cinaver

What Cinaver treats: Main Uses and Benefits

Cinaver is a supportive medication generally used to provide targeted symptomatic relief and is commonly applied across domains where additional symptomatic support is needed. The medication is generally applied in contexts marked by increased discomfort or tension and helps manage symptoms that interfere with daily functioning.

Easing Acute Symptom Severity

The provision of symptomatic relief is a relevant factor in patient comfort. Cinaver is commonly used when symptoms appear suddenly or intensify over time, and may be part of symptomatic management in situations where patients experience noticeable physiological strain. It is applied during episodes marked by heightened physiological activity to assist with managing the symptom intensity, and supports general well-being during symptomatic phases. This medicine is relevant for easing symptom intensity, pronounced symptoms, and situations with significant discomfort.

Supportive medication supports the patient during difficult episodes by easing distress.

Supportive Management of Distressing Manifestations

The medication is relevant in conditions involving episodic or fluctuating manifestations that present with systemic or localized discomfort. Cinaver helps address symptom clusters that create noticeable functional strain, particularly those associated with acute or disruptive episodes. This application supports patients during episodes of heightened discomfort by helping to ease the overall symptom load and provides supportive relief when symptoms interfere with routine activities. It offers symptomatic relief that assists with maintaining functional stability.


Quick Fact: Relevant for Symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Eligibility for Cinaver (Cinnarizine) is defined by official regulatory labeling across age, pre-existing conditions, and physiological states. The medicine is permitted for adults and children aged 5 years and over.


Absolute Contraindications

Cinaver must not be used in the presence of specific conditions, including:

  • Known hypersensitivity to cinnarizine or any of its excipients.
  • Porphyria (an inherited blood disorder).
  • Severe hepatic impairment (severe liver disease).
  • Severe renal impairment (kidney function below the officially specified clearance level).

Conditional Use and Restrictions

Use of this medicine requires particular caution or is formally not recommended for several populations. It is not recommended for women who are pregnant or breastfeeding due to safety data not being established. Conditional use applies to patients with Parkinson's disease, angle-closure glaucoma, urinary retention, or epilepsy, where the risk of symptom aggravation or complication requires careful consideration. Patients with mild to moderate hepatic or renal impairment must also use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cinaver's official regulatory profile documents specific interaction patterns concerning its effects on the central nervous system (CNS) and its pharmacokinetic clearance pathway.

Interacting Product Categories and Effects

Classification Official Regulatory Statement
Pharmacodynamic Interaction Concurrent use of alcohol, CNS depressants, or tricyclic antidepressants may potentiate the sedative effects of the co-administered drug or Cinaver.
Pharmacokinetic Mechanism The medicine undergoes extensive metabolism mainly via the CYP2D6 enzyme system.
Procedural Constraint Due to its antihistamine effect, Cinaver may prevent an otherwise positive reaction to dermal reactivity indicators if used up to 4 days prior to skin testing.

This structure reflects the documented risks of pharmacodynamic augmentation, where the drug's inherent sedative properties are enhanced by co-administered CNS depressants. The inclusion of the CYP2D6 clearance pathway identifies the main metabolic route, which indicates susceptibility to interactions with substances that modulate this enzyme. Furthermore, the profile specifies a mandatory timing separation requirement for certain diagnostic procedures.

Mechanism of Action

How Cinaver Works: Mechanisms of Action

Cinaver's action is defined by two primary mechanistic domains that result from molecular interactions that modulate excessive signaling and influence local circulation.


Dampening Vestibular Signal Transmission

This domain covers the drug's effect as a first-generation H₁ antagonist and its action on neural excitability. It primarily targets the Histamine H₁ receptors in the central nervous system, particularly the brain's balance coordination centers. This interaction works to block the excitatory signaling driven by histamine, reducing the transmission of excessive neural activity from the inner ear. The resulting physiological effect is the modulation of the equilibrium signal processed by the central nervous system.


Dual Modulation via Calcium Channel Blockade

This mechanism involves the non-competitive blockade of Ca^2+ channels on two key cellular sites: the sensory hair cells of the inner ear and the vascular smooth muscle in the brain's microcirculation. By restricting the necessary Ca^2+ influx, the drug diminishes the peripheral signaling from the sensory cells while simultaneously inducing vasorelaxation in local blood vessels. This combined action influences the supply of oxygen and nutrients to the inner ear structures, influencing their function and contributing to the modulation of physiological state.

Dosage and Administration Information

How to use Cinaver: Administration Guidelines

This section outlines the administration parameters for Cinaver (Cinnarizine).


Administration Scope

Instruction Detail
Route of administration: Oral. The medication is administered by mouth as a tablet or capsule.
Dosing schedule: For continuous use, the typical dose is 25 mg three times daily (75 mg total), with a maximum recommended daily dose of 225 mg.
Timing in relation to meals (if applicable): Cinaver should preferably be taken after meals to diminish the potential for gastric irritation.
Preparation requirements (if applicable): No dilution or reconstitution is required; tablets can be swallowed whole, sucked, or chewed.
Age-group administration rules: For children aged 5 to 12 years, the recommended dose for both contexts is half the adult dose.
Missed-dose rules: If a dose is forgotten, subsequent doses must maintain a minimum interval of 8 hours.
Special procedural conditions: For intermittent use (e.g., motion sensitivity), the initial dose must be administered 30 minutes to 2 hours prior to the start of travel.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral
Frequency pattern: Multiple times daily (TID) or Intermittent/As-Needed.
Instruction Type: Standardized product characteristics.
Use-context constraints: The instruction defines a choice between Short-Term/Intermittent use or Continuous/Maintenance use.

Resulting Procedural Structure

The usage protocol for Cinaver is defined by two primary administration patterns: a continuous, divided daily regimen for ongoing management and an intermittent regimen tied to a specific pre-event timing. This structure specifies the oral route, sets the maximum dose, and provides rules for pediatric use, establishing a consistent approach to administration.

Recent Clinical Evidence

Cinaver: Recent Clinical Evidence

Evidence on Mechanism and Efficacy

Studies evaluated the compound's potential to affect inflammatory markers. Research has also investigated whether the combination of the two may be associated with patient outcomes in the studied population.

The first set of studies evaluated the drug’s performance in the context of pain. Researchers noted changes in self-reported pain among participants. This research examined changes in reported pain and mobility.


Key Clinical Findings

Trial 1: Pain and Symptom Duration

A subsequent trial evaluated the compound against a placebo in participants with mild to moderate symptoms. The findings indicated that some participants reported a longer duration of change in symptoms.

Trial 2: Combination Therapy

Researchers investigated whether the combination might influence markers associated with the condition. Research assessed the compound's anti-inflammatory properties.

The studies monitored interactions when the compound was used alongside other common medications.

Frequently Asked Questions (FAQ)

Common questions about Cinaver (FAQ)


Q: What is Cinaver used for besides its main listed purpose?

Official regulatory documents indicate that Cinaver is approved for managing symptoms related to a range of inner ear and balance disorders. This includes conditions such as vertigo, tinnitus, and Ménière's disease. In some regulatory jurisdictions, evidence also supports its use for managing peripheral vascular disorders, which involve circulation issues.

Q: How is Cinaver different from other similar medicines?

Cinaver's unique characteristic, according to pharmacological classification, is its dual mechanism of action. It functions both as a first-generation antihistamine and as a calcium channel blocker (CCB). This profile allows it to influence both the nerve signaling in the inner ear and the local blood flow in the balance centers of the brain.

Q: What types of food or drink are known to interact with Cinaver?

Official product information notes that the concurrent use of alcohol is generally not recommended while using this medicine. This is because alcohol may increase the sedative side effects of Cinaver, potentially leading to increased drowsiness. Typically, specific food interactions are not documented in the regulatory labeling.

Q: Can you take Cinaver with common over-the-counter pain relievers or cold medicines?

The regulatory warnings focus on avoiding concurrent use with any medicine that may cause drowsiness or sedation. Since many common cold and pain medicines contain ingredients that cause these effects, caution is generally noted in regulatory information. Warnings are often linked to the sedative effects common to many cold and pain medicines.

Q: Does Cinaver interact with common blood pressure or cholesterol medications?

Regulatory caution exists because Cinaver has vasodilatory effects, meaning it can influence blood vessel tone and potentially lower blood pressure. Although some low-dose labels report no known interactions with specific antihypertensive or cholesterol-lowering medications, regulatory information notes that awareness is required due to its potential effect on blood pressure.

Q: Is Cinaver okay to take while planning a pregnancy or trying to conceive?

Official safety data is not explicitly available for the pre-conception or planning stage. However, the medicine is generally not recommended for women who are already pregnant or breastfeeding. It is classified as a Category C medicine for pregnancy, indicating that use is typically restricted unless strictly necessary.

Q: Is there a difference in efficacy between the tablet form and the capsule form of Cinaver?

Official regulatory standards consider different oral dosage forms, such as tablets and capsules, to be therapeutically equivalent. While no difference in overall efficacy is usually noted, official documentation notes that the tablet form may have additional administration options, such as being chewed or sucked.

Q: Why do people online say Cinaver works better when taken at night?

According to official adverse reactions data, Cinaver commonly causes side effects such as drowsiness or sleepiness. Taking the medicine at night is a common strategy reported to help mitigate this sedative effect during the daytime.

Q: Does Cinaver affect the results of common blood tests?

Regulatory labeling specifically notes a procedural constraint concerning the results of dermal reactivity indicators, which are allergy skin tests. There is no explicit regulatory warning or instruction given regarding the effect of Cinaver on the results of common blood tests.

Q: Does taking certain vitamins or herbal supplements affect Cinaver?

Official regulatory summaries typically do not contain enough information to confirm the safety of using all possible vitamins or supplements concurrently. However, official summaries often suggest awareness regarding herbal remedies or supplements that may cause side effects similar to Cinaver, such as drowsiness or dry mouth.

Q: How soon after starting Cinaver do people usually see the maximum benefit?

For immediate use, such as for motion sensitivity, the medicine works gradually and is often noted to reach its full effect within up to four hours after the initial dose. For chronic conditions, the full benefit may take longer to achieve.

Q: What happens if you stop taking Cinaver suddenly?

For chronic conditions, especially inner ear problems, official regulatory texts advise that symptoms may return or worsen if the medicine is discontinued. Official regulatory texts stress the importance of following the prescribed duration of use to help avoid a return of symptoms.

Q: Can people with diabetes safely use Cinaver?

Diabetes is generally not listed as a specific caution or contraindication for the medicine. Furthermore, at least one low-dose label reports no known interactions with medications used to manage blood sugar, known as hypoglycaemics.

Q: Has Cinaver been approved in other countries yet?

Yes, official regulatory guidance confirms that the medicine is approved for use under various trade names and is available across multiple jurisdictions globally. Regulatory agencies such as the MHRA and Health Canada provide oversight for the product.

Q: Is the manufacturing or source of Cinaver regulated by a government body?

All prescription and pharmacy medicines are subject to the standards and oversight of national regulatory agencies, such as the FDA or EMA. These bodies regulate the product quality and manufacturing processes to ensure consistency and patient safety.

Q: Is Cinaver available over the counter or only with a prescription?

The status of the drug varies depending on the country and the specific dosage strength. It can be available for purchase at a pharmacy for certain conditions like travel sickness, or it may require a prescription for chronic inner ear conditions.

How should Cinaver be stored and disposed of?

How to Store and Dispose of Cinaver?

Cinaver's official storage and disposal requirements are set by regulatory agencies to ensure product stability and safety. The medicine must be stored under specific environmental constraints and protected from misuse.


Official Storage Requirements

To maintain the drug's integrity, Cinaver tablets must be stored at temperatures not exceeding 30 C and protected from light. It is mandatory to keep out of the sight and reach of children at all times. The medicine must not be used after the expiry date printed on the packaging.

Disposal Instructions

When discarding unused or expired Cinaver, do not throw away any medicines via wastewater or household waste. Disposal must be performed in accordance with local requirements, which often involves returning the product to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinaver found in:

A-Z Index: